Envestnet Asset Management Inc. boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) by 94.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 251,391 shares of the company's stock after acquiring an additional 122,169 shares during the period. Envestnet Asset Management Inc.'s holdings in Fresenius Medical Care AG & Co. KGaA were worth $8,467,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in FMS. Pzena Investment Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 47.6% in the fourth quarter. Pzena Investment Management LLC now owns 9,459,446 shares of the company's stock valued at $307,054,000 after buying an additional 3,051,672 shares during the last quarter. First Trust Advisors LP raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 15.1% in the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company's stock valued at $62,496,000 after buying an additional 252,768 shares during the last quarter. Cambiar Investors LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 18.3% in the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company's stock valued at $45,935,000 after buying an additional 210,819 shares during the last quarter. Invesco Ltd. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 54.0% in the fourth quarter. Invesco Ltd. now owns 376,173 shares of the company's stock valued at $12,211,000 after buying an additional 131,870 shares during the last quarter. Finally, Timber Creek Capital Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.1% in the first quarter. Timber Creek Capital Management LLC now owns 198,743 shares of the company's stock valued at $6,693,000 after buying an additional 9,695 shares during the last quarter. Institutional investors and hedge funds own 4.73% of the company's stock.
Get Fresenius Medical Care AG & Co. KGaA alerts:Fresenius Medical Care AG & Co. KGaA Price Performance
FMS opened at $18.66 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt-to-equity ratio of 0.47. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $18.16 and a 52-week high of $40.85. The company has a 50 day moving average of $24.13 and a two-hundred day moving average of $29.46. The company has a market cap of $10.94 billion, a P/E ratio of 11.89, a P/E/G ratio of 0.92 and a beta of 1.03.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on FMS. StockNews.com lowered shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 15th. JPMorgan Chase & Co. dropped their price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Friday, July 29th. DZ Bank lowered shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a research report on Friday, July 29th. Finally, Truist Financial dropped their price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a research report on Wednesday, June 22nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA presently has an average rating of "Hold" and a consensus price target of $49.01.Fresenius Medical Care AG & Co. KGaA Profile
(Get Rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
- Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- Can Etsy Continue to Thrive After the Pandemic?
- MarketBeat Podcast: Investing in What You Know Has Changed
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.